1. Home
  2. PHGE

PHGE

BiomX Inc. COmmon Stock

Logo BiomX Inc. COmmon Stock

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-19-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF.

Founded: 2015 Country:
Israel
Israel
Employees: N/A City: NESS ZIONA
Market Cap: 16.0M IPO Year: N/A
Target Price: $2.00 AVG Volume (30 days): 2.7M
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.51 EPS Growth: N/A
52 Week Low/High: $0.19 - $0.85 Next Earning Date: 04-03-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: